TABLE 16Remissiona rates for responders reported at weeks 30 and 54 in ACCENT I2,3

Dose regimen (n)Week 30Week 54
Remission: % (95% CIb) (number)Odds ratio (95% CI) intervention/placebopcRemission (%)dpc
Placebo (110)21% (14% to 29%) (23)NRNA14%NA
5 mg/kg group (113)39% (30% to 48%) (44)NR0.00328%0.007
10 mg/kg group (112)45% (36% to 55%) (50)NR0.00238%< 0.0001
5 mg/kg and 10 mg/kg groups combined (225)42% (36% to 48%) (94)2.7 (1.6 to 4.6)NR33%

NA, not applicable; NR, not reported.

a

Remission defined as a CDAI < 150 and no requirement for change in medication or for surgery.

b

Calculated from published values.

c

Intervention vs placebo.

d

Data read from published graph in Hanaeur et al.3

Remission defined as a CDAI < 150 and no requirement for change in medication or for surgery.

Calculated from published values.

Intervention vs placebo.

Data read from published graph in Hanaeur et al.3

From: 3, Assessment of clinical effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.